AstraZeneca focuses on long-term oncology strategy, shares anchored in the FTSE 100

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 09:01.

AstraZeneca (GB0009895292) stands as one of the largest pharmaceutical names in the FTSE 100, with a market capitalization above 220 billion pounds according to recent London Stock Exchange data. The stock trades under the ticker AZN on the London Stock Exchange, and investors continue to focus on its long-term strategy in oncology and other specialty medicines.

What long-term strategy shows

AstraZeneca’s published strategy emphasizes a focus on oncology, biopharmaceuticals and rare disease, building on existing franchises in lung, breast, ovarian and hematologic cancers according to its investor materials. The company stresses its aim to deliver innovative medicines through targeted therapies, immuno-oncology and antibody-drug conjugates, supported by a broad pipeline of phase III and earlier-stage assets.

The group also highlights its long-term ambition to grow in cardiovascular, renal and metabolic diseases, as well as respiratory and immunology, leveraging established brands and newer biologics. In rare disease, the integration of Alexion has added a portfolio of medicines in complement inhibition and other ultra-rare indications, which AstraZeneca views as a durable growth platform.

How consensus views the company

Analyst consensus collected by MarketScreener and similar platforms shows most major houses such as Goldman Sachs, UBS and Barclays maintaining broadly constructive views on AstraZeneca, with a majority of ratings in the Buy or Outperform range. Price targets cluster notably above the current share price, signaling expectations for continued earnings growth driven largely by oncology and rare disease franchises.

Recent notes from these houses point to key assets such as Tagrisso (osimertinib) in lung cancer and Imfinzi (durvalumab) in immuno-oncology as central earnings drivers, alongside newer launches and line extensions. Analysts also track the contribution from rare disease medicines, where Alexion’s portfolio has expanded AstraZeneca’s exposure to high-margin, specialist therapies.

The product behind the stock

AstraZeneca generates a significant share of its revenue from oncology medicines, with Tagrisso, a targeted therapy for EGFR-mutated non-small cell lung cancer, among its largest products. Tagrisso is approved in major markets including the US, EU and Japan for various lines of therapy, and has become a cornerstone treatment in its segment.

Where the stock trades today

The AstraZeneca shares (GB0009895292) most actively trade on the London Stock Exchange under the ticker AZN, with the latest available quote on a recent trading day showing around 14,038 pence per share and a market capitalization of roughly 222 billion pounds as reported by UK price services.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or any other form of financial guidance. All data are based on publicly available sources believed to be reliable at the time of publication, but no guarantee is given for completeness or accuracy. Investors should conduct their own research or consult a qualified advisor before making investment decisions.